182 related articles for article (PubMed ID: 19817942)
1. Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Ferdinand KC; Flack JM; Saunders E; Victor R; Watson K; Kursun A; Jamieson MJ; Shi H
J Clin Hypertens (Greenwich); 2009 Oct; 11(10):585-93. PubMed ID: 19817942
[TBL] [Abstract][Full Text] [Related]
2. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Flack JM; Victor R; Watson K; Ferdinand KC; Saunders E; Tarasenko L; Jamieson MJ; Shi H; Bruschi P
Mayo Clin Proc; 2008 Jan; 83(1):35-45. PubMed ID: 18174006
[TBL] [Abstract][Full Text] [Related]
3. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
4. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM;
Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012
[TBL] [Abstract][Full Text] [Related]
5. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Richard Hobbs FD; Gensini G; John Mancini GB; Manolis AJ; Bauer B; Genest J; Feldman RD; Harvey P; Jenssen TG; da Silva PM;
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):472-80. PubMed ID: 19407658
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Grimm R; Malik M; Yunis C; Sutradhar S; Kursun A;
Vasc Health Risk Manag; 2010 May; 6():261-71. PubMed ID: 20479948
[TBL] [Abstract][Full Text] [Related]
7. Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Oliver S; Jones J; Leonard D; Crabbe A; Delkhah Y; Nesbitt S
J Clin Hypertens (Greenwich); 2011 Aug; 13(8):598-604. PubMed ID: 21806770
[TBL] [Abstract][Full Text] [Related]
8. [One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Simonyi G; Ferenci T
Orv Hetil; 2016 Mar; 157(11):425-9. PubMed ID: 26947091
[TBL] [Abstract][Full Text] [Related]
9. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
10. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
McKenney JM; Davidson MH; Saponaro J; Thompson PD; Bays HE
J Cardiovasc Pharmacol; 2005 Nov; 46(5):594-9. PubMed ID: 16220065
[TBL] [Abstract][Full Text] [Related]
11. Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Curran MP
Drugs; 2010; 70(2):191-213. PubMed ID: 20108992
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Preston RA; Harvey P; Herfert O; Dykstra G; Jukema JW; Sun F; Gillen D
J Clin Pharmacol; 2007 Dec; 47(12):1555-69. PubMed ID: 18048574
[TBL] [Abstract][Full Text] [Related]
13. Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Neutel JM; Eaddy M; Lunacsek OE; Roberts C; Chen L; Kean AJ; Jackson JH
J Clin Hypertens (Greenwich); 2010 Jun; 12(6):396-406. PubMed ID: 20591084
[TBL] [Abstract][Full Text] [Related]
14. A single-pill combination of amlodipine besylate and atorvastatin calcium.
Blank R
Drugs Today (Barc); 2006 Mar; 42(3):157-75. PubMed ID: 16628258
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Naydenov Naydenov S; Margaritov Runev N; Ivanov Manov E; Georgieva Torbova-Gigova S
Acta Clin Croat; 2018 Sep; 57(3):464-472. PubMed ID: 31168179
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Cowie MR
Int J Clin Pract; 2005 Jul; 59(7):839-46. PubMed ID: 15963213
[TBL] [Abstract][Full Text] [Related]
18. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Blank R; LaSalle J; Reeves R; Maroni J; Tarasenko L; Sun F
J Clin Hypertens (Greenwich); 2005 May; 7(5):264-73. PubMed ID: 15886529
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
[TBL] [Abstract][Full Text] [Related]
20. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
Fedacko J; Pella D; Jarcuska P; Sabol F; Kmec J; Lopuchovsky T; Merkovska L; Jedlickova L; Janicko M; Sajty M
Adv Ther; 2013 Jan; 30(1):60-70. PubMed ID: 23328937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
